1500 E. Duarte RoadDuarte, CA 91010
Overview of Dr. Shreenivas
I am a medical oncologist with a clinical practice in gastrointestinal and rare cancers. From a research standpoint, I am primarily affiliated with City of Hope 's early drug development program. Our group believes in the concept of vertical research, and the overall thrust of my research work has been focused on creating a small but significant impact in a few areas of oncology. They are as follows: 1) improve our understanding of radiation and immunotherapy resistance patterns and develop clinical trial concepts of novel multimodal therapeutic approaches in head& neck and gastrointestinal cancers. 2) develop pilot projects to better understand the role of tumor-informed circulating tumor DNA assays in response assessments. 3) utilization of individualized and personalized molecular-based therapies for the management of rare cancers, and finally 4) survivorship care and symptom management.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2015 - 2018
BronxCare Health SystemResidency, Internal Medicine, 2012 - 2015
JSS Medical College MysoreClass of 2010
Icahn school of medicine Newyork MSCR, Clinical research
Certifications & Licensure
CA State Medical License 2024 - 2026
NY State Medical License 2015 - 2026
WI State Medical License 2018 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.Stacey A Cohen, Vasily N Aushev, George Laliotis, Iktej S Jabbal, Arun Nagarajan
Annals of Surgery. 2025-08-07 - Successful Targeting of SomaticAlterations With Belzutifan in Two Cases.Bicky Thapa, Aditya Shreenivas, Kathryn Bylow, Hui-Zi Chen, Ben George
Journal of Immunotherapy and Precision Oncology. 2024-11-01 - Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy.Sewanti Limaye, Mohan Menon, Shambhavi Singh, Pritam Kataria, Aditya V Shreenivas
Journal of Immunotherapy and Precision Oncology. 2024-08-01
Press Mentions
City of Hope Research Showcases Innovation at 2025 AACR Annual MeetingMay 16th, 2025- City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual MeetingApril 25th, 2025
Their cancers can't be cured. But new treatments are increasing the length, and quality, of their lives.June 13th, 2024- Join now to see all
Grant Support
- Cancer Center Pilot GrantMedical College of WisconsinPresent
- NRG NCORP GrantNRGPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
